Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03860792 · ClinicalTrials.gov registry record · NA
Therapeutic Diets in Alzheimer's Disease
A NA study of Alzheimer Disease, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT03860792: Completed NA study of Alzheimer Disease, sponsored by University of Kansas Medical Center.
NCT03860792 is a NA study of Alzheimer Disease that has completed, run by University of Kansas Medical Center. The registered enrollment target is 84 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03860792, a NA study of Alzheimer Disease, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
By doing this study, researchers hope to learn how the ketogenic and Therapeutic Lifestyles Changes diets affect cognition in patients with Alzheimer's disease.
Primary Outcome
Cognitive performance will be assessed by a psychometrician using the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADASCog11). The ADAS-Cog is an Alzheimer's disease specific, multi-domain cognitive assessment scored from 0-70 points with higher scores indicating poorer cognitive performance.
Conditions Studied
Interventions
- BEHAVIORAL Ketogenic Diet
- BEHAVIORAL Therapeutic Lifestyles Changes Diet
Study Locations (1)
Kansas
- Clinical and Translational Science Unit - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2025-06-20 |
| Phase | NA |
What the finished NCT03860792 record still lists
NCT03860792 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Ketogenic Diet is the first listed.
NCT03860792 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03860792 about?
NCT03860792 is a clinical study titled "Therapeutic Diets in Alzheimer's Disease". By doing this study, researchers hope to learn how the ketogenic and Therapeutic Lifestyles Changes diets affect cognition in patients with Alzheimer's disease.
What is the current status of trial NCT03860792?
This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2019-10-15. Estimated completion is 2025-06-20.
What conditions does trial NCT03860792 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03860792?
The interventions under investigation include: Ketogenic Diet (BEHAVIORAL), Therapeutic Lifestyles Changes Diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT03860792?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03860792 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03860792's enrollment target sits among peer trials
84 166th of 306 higher than 141 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI